Eligibility Module

Eligibility Module

The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.

Eligibility Module path is as follows:

Study -> Protocol Section -> Eligibility Module

Eligibility Module


Ignite Creation Date: 2025-12-24 @ 1:17 PM
Ignite Modification Date: 2025-12-24 @ 1:17 PM
NCT ID: NCT04723095
Eligibility Criteria: Inclusion Criteria: * Patients with a personal history of cervical cancer with any portion of neuroendocrine component (including mixed tumors) of the following histologic subtypes: * Small cell neuroendocrine carcinoma * Large cell neuroendocrine carcinoma * Undifferentiated high-grade neuroendocrine carcinoma * Patients may be in any stage of treatment, surveillance or recurrence at the time of initial participation in the study * Patients with all stages of disease are considered eligible * Patients who do not speak English can be eligible if accompanied by an institutional interpreter * Patients who are receiving or have received treatment at any facility, including but not limited to M. D. Anderson Cancer Center are eligible * Patient may be residents of any country and be of any ethnic background * Patients who request to participate in the study, regardless of the method by which they learned of it, are eligible to participate, including, but not limited to patients who seek participation via the website * Next of kin or legal authorized representatives of patients who are deceased but had a history of neuroendocrine carcinoma (NEC) of the cervix are eligible to participate * Next of kin or legal authorized representatives of patients must read and speak English Exclusion Criteria: * Patients with other histologic subtypes of NEC of the cervix including typical and atypical carcinoid tumors
Healthy Volunteers: False
Sex: ALL
Study: NCT04723095
Study Brief:
Protocol Section: NCT04723095